Treace Medical Concepts, Inc.
TMCI Healthcare Medical Devices
Treace Medical Concepts, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $212.7 million, up 1.59% from fiscal 2024. In the quarter to June 2026, revenue fell 4.24%, EPS grew 14.3%, free cash flow grew 11.7% and total debt rose 4.84%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow TMCI
Treace Medical Concepts, Inc. (TMCI) EV/Sales
As of 16 October 2026, Treace Medical Concepts, Inc. (TMCI) trades at a EV/Sales of 1.3×. Over the past ten years it has ranged from 0.4× (March 2026) to 21.3× (June 2021); the current reading is higher than 11% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.8× | (63.44%) |
| FY2024 | 2.1× | (43.29%) |
| FY2023 | 3.7× | (56.44%) |
| FY2022 | 8.5× | (2.64%) |
| FY2021 | 8.8× | (42.09%) |
| FY2020 | 15.1× | 0.00% |
| FY2019 | 15.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.3× | 196.61% |
| Mar 2026 | 0.4× | (42.26%) |
| Dec 2025 | 0.8× | (60.20%) |
| Sep 2025 | 1.9× | 16.20% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LAB Standard BioTools Inc. compare | −2.7× |
| TMCI Treace Medical Concepts, Inc. | 1.3× |
| INFU InfuSystems Holdings, Inc. compare | 2.0× |
| ELMD Electromed, Inc. compare | 2.8× |
| TLSI TriSalus Life Sciences, Inc. compare | 4.4× |
| CLPT ClearPoint Neuro, Inc. compare | 7.0× |
| PROF Profound Medical compare | 9.9× |
| CATX Perspective Therapeutics, Inc. compare | 64.7× |
| QSI Quantum-Si Incorporated compare | 82.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)